#Pfizer

ViiV alleges that the bictegravir component of the tablet infringes on its own patent for Tivicay (dolutegravir).

“Bicillin is the only treatment for pregnant women with syphilis, and Pfizer has the exclusive patent.”

The sale includes an HIV attachment inhibitor called fostemsavir and a maturation inhibitor, both in late-stage development.

GlaxoSmithKline (GSK) has joined with University of North Carolina at Chapel Hill to pursue HIV cure strategies.

Pharma giant GlaxoSmithKline (GSK) might plan an initial public offering (IPO) of a minority stake in ViiV Healthcare, which makes new HIV med...

With the mutation, people seem to make slightly more insulin and have slightly lower blood glucose levels than normal throughout their lives.

A leaked email has revealed efforts by the international drug industry to influence reforms to South African intellectual property law.

A new fund allows investors to finance late-stage global health technologies in low-income countries.

The FDA has granted ViiV Healthcare priority review designation for the company’s new integrase inhibitor dolutegravir.

More than 40 chief executive officers from major companies have signed a pledge urging 45 countries to lift their t...

ViiV Healthcare, an HIV company formed by Pfizer and GlaxoSmithKline, has established a pharmaceutical manufacturing partnership with Russian...

ViiV Healthcare—an HIV drug company created in 2009 by GlaxoSmithKline and Pfizer—will not spin off into a public company any time soon.

ViiV Healthcare, which makes several antiretroviral (ARV) drugs, is expanding programs to help HIV-positive people access the company’s...

People who failed treatment on the entry inhibitor Selzentry had good long-term health outcomes after switching their antiretroviral (ARV) reg...

ViiV Healthcare, a global HIV-focused company launched by GlaxoSmithKline and Pfizer in 2009, is seeking requests for grants for programs focu...

In honor of World AIDS Day, AIDSmeds highlights the year’s top treatment stories.